Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling, simulation, and analysis to accelerate and de-risk drug research and development, today announced their participation at the ICI-IO Combinations Summit occurring March 19-21, 2019 in Boston, MA.

John Burke, PhD, Co-Founder, President and CEO, Applied BioMath is presenting "Model Aided Drug Invention Case Study: GITR-mediated T cell Dynamics in Mouse Tumor Micro Environment" on Wednesday, March 20, 2019 at 9:40a.m.

In this presentation Dr. Burke will review a collaboration where a Model Aided Drug Invention approach was used to develop and analyze a systems pharmacology model of an anti-GITR (Glucocorticoid-Induced TNFR Related protein) agonist antibody to predict Treg and Teff dynamics in the tumor microenvironment in two syngeneic mouse models following administration of anti-GITR agonist antibody.

Model-Aided Drug Invention (MADI) is a rigorous fit-for-purpose model development process which aims to quantitatively integrate knowledge about therapeutics with an understanding of its mechanism of action in the context of human disease mechanisms.

"This case study is one of many examples of how MADI can be applied to various indications and throughout all phases in drug R&D," said John Burke, PhD, Co-Founder, President and CEO, Applied BioMath. "MADI continues to hold its track record of successfully helping biotechnology and pharmaceutical companies de-risk projects, accelerate development of best-in-class therapeutics, and reduce late stage attrition rates; ultimately resulting in making better therapeutics, which improve patients' lives."

In addition to their presentation, Applied BioMath will have a booth throughout the conference. For more information about Applied BioMath's presence at the ICI-IO Combinations Summit visit https://www.appliedbiomath.com/news-resources/events/ici-io-combinations-summit.

For more information about Applied BioMath's upcoming events, visit www.appliedbiomath.com/news-resources/events.

About Applied BioMath

Founded in 2013, Applied BioMath uses mathematical modeling and simulation to provide quantitative and predictive guidance to biotechnology and pharmaceutical companies to help accelerate and de-risk drug research and development.  Their Model-Aided Drug Invention (MADI) approach employs proprietary algorithms and software to support groups worldwide in decision-making from early research through clinical trials.  The Applied BioMath team leverages their decades of expertise in biology, mathematical modeling and analysis, high-performance computing, and industry experience to help groups better understand their candidate, its best-in-class parameters, competitive advantages, patients, and the best path forward into and in the clinic.   For more information about Applied BioMath and its services, visit www.appliedbiomath.com.

Applied BioMath and the Applied BioMath logo are registered trademarks of Applied BioMath, LLC.

Press contact:
Kristen Zannella
kristen.zannella@appliedbiomath.com